March 24, 2020 / 12:38 PM / 10 days ago

BRIEF-Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies

March 24 (Reuters) - Allogene Therapeutics Inc:

* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND COMMERCIAL LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T (ALLOCAR T™) THERAPIES

* ALLOGENE THERAPEUTICS - AGREEMENT ENABLES ALLOGENE TO UTILIZE MAXCYTE’S EXPERT PLATFORM IN TARGET CANDIDATES

* ALLOGENE THERAPEUTICS INC - UNDER TERMS, MAXCYTE TO GET UNDISCLOSED DEVELOPMENT, APPROVAL & COMMERCIAL MILESTONES IN ADDITION TO OTHER LICENSING FEES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below